KBC Group NV Has $41.53 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

KBC Group NV decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 115,886 shares of the biotechnology company's stock after selling 42,455 shares during the quarter. KBC Group NV owned 0.26% of United Therapeutics worth $41,528,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. LSV Asset Management boosted its stake in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after acquiring an additional 436,851 shares during the period. Swedbank AB purchased a new stake in shares of United Therapeutics in the first quarter worth approximately $97,316,000. Canada Pension Plan Investment Board increased its holdings in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock worth $41,533,000 after purchasing an additional 153,700 shares during the period. Assetmark Inc. increased its holdings in United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock worth $150,492,000 after purchasing an additional 152,249 shares during the period. Finally, Pacer Advisors Inc. boosted its position in United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after acquiring an additional 92,240 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent analyst reports. Bank of America lowered their price objective on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research report on Thursday, August 1st. The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research note on Friday, November 1st. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Finally, LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 224 shares of the company's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares of the company's stock, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $1,034,510.88. This trade represents a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,396 shares of company stock worth $42,175,418 in the last three months. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Down 6.0 %

Shares of UTHR stock traded down $23.02 during trading on Friday, hitting $363.25. The company had a trading volume of 619,975 shares, compared to its average volume of 463,344. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The stock's 50-day moving average is $362.57 and its two-hundred day moving average is $326.65. The stock has a market capitalization of $16.22 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. During the same period last year, the firm posted $5.38 earnings per share. The business's revenue for the quarter was up 22.9% on a year-over-year basis. On average, research analysts predict that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.